R Donald Harvey III PharmD

Affiliations:

No affiliations have been saved.

External Links (e.g. Departmental web site):

No external links have been saved.

Degrees Held:

No degrees have been saved.

Research Interests:

No research interests have been saved.

Biography/Description of Research:

No biography information has been saved.

Works 1-10 of 47

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Article

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

by A Craig Lockhart; Todd M. Bauer; Charu Aggarwal; Carrie B. Lee; R Donald Harvey; Roger B. Cohen; Farhad Sedarati; Tsz Keung Nip; Hélène Faessel; Ajeeta B. Dash; Bruce J. Dezube; Douglas V. Faller; Afshin Dowlati

2019

Article

Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors

by Michael S. Gordon; Geoffrey I. Shapiro; John Sarantopoulos; Dejan Juric; Brian Lu; Angeliki Zarotiadou; Jamie N. Connarn; Yvan Le Bruchec; Calin Dan Dumitru; R Donald Harvey

2022

Article

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

by Jatin J. Shah; Andrzej J. Jakubowiak; Owen A. O'Connor; Robert Z. Orlowski; R. Harvey; Mitchell R. Smith; Daniel Lebovic; Catherine Diefenbach; Kevin Kelly; Zhaowei Hua; Allison J. Berger; George Mulligan; Helene M. Faessel; Stephen Tirrell; Bruce J. Dezube; Sagar Lonial

2016

Article

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling

by Neeraj Gupta; Paul M. Diderichsen; Michael J. Hanley; Deborah Berg; Helgi van de Velde; R. Harvey; Karthik Venkatakrishnan

2017

Article

Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

by Stephen I Shibata; Vincent Chung; Timothy Synold; Jeffrey Longmate; A Benjamin Suttle; Lone H Ottesen; Heinz-Josef Lenz; Shivaani Kummar; R. Harvey; Anne Hamilton; Bert O'Neil; John Sarantopoulos; Patricia LoRusso; Michelle A Rudek; Afshin Dowlati; Daniel Mulkerin; Chandra P. Belani; Leena Gandhi; Cecilia Lau; S. Percy Ivy

2013

Article

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

by David Siegel; Thomas Martin; Ajay Nooka; R. Harvey; Ravi Vij; Ruben Niesvizky; Ashraf Z. Badros; Sundar Jagannath; Leanne McCulloch; Kanya Rajangam; Sagar Lonial

2013

Article

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies

by R. Harvey; Taofeek Owonikoko; C M Lewis; A Akintayo; Z Chen; M Tighiouart; Suresh Ramalingam; MP Fanucchi; P Nadella; A Rogatko; Dong Shin; Bassel El-Rayes; FR Khuri; JS Kauh

2013